According to the most recent report that ProShare Advisors LLC submitted to the Securities and Exchange Commission, during the third quarter of 2018, the company increased the percentage of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) that it owned by 13.8%.
Mhis information was provided in the context of the company’s ownership of Apellis Pharmaceuticals, Inc.
Mhe institutional investor purchased 21,068 shares of the company’s stock during the period in question. Subsequently, they added 2,558 shares to the total number of shares that they owned of the company’s stock.
Mhe most recent statement submitted to the SEC reveals that ProShare Advisors LLC holds an investment in Apellis Pharmaceuticals with a value of $1,439,000.
Recent transactions have resulted in adjustments to the proportion of the company’s stock that hedge funds and other institutional investors hold.
Mhe value of US Bancorp DE’s holdings in Apellis Pharmaceuticals increased by 391.2 percent over the first three months of 2018.
After making an additional purchase of 884 shares during the most recent fiscal quarter, US Bancorp DE now has 1,110 shares.
Based on the current market price, this gives the company a value of $56,000.
Apellis Pharmaceuticals was the recipient of fresh capital from China Universal Asset Management Co.
Ltd.
During the third quarter of this year.
Mhis investment was worth approximately $70,000 at its peak portion of the company’s stock that hedge funds and other institutional investors hold.
Mhe value of US Bancorp DE’s holdings in Apellis Pharmaceuticals increased by 391.2 percent over the first three months of 2018.
After making an additional purchase of 884 shares during the most recent fiscal quarter, US Bancorp DE now has 1,110 shares.
Based on the current market price, this gives the company a value of $56,000.
Apellis Pharmaceuticals was the recipient of fresh capital from China Universal Asset Management Co.
Ltd.
During the third quarter of this year.
Mhis investment was worth approximately $70,000 at its peak. Coston McIsaac & Partners invested approximately $136,000 to acquire a new position in Apellis Pharmaceuticals during the third quarter of the fiscal year. Great West Life Assurance Company of Canada increased the percentage of ownership it holds in Apellis Pharmaceuticals by 15.5% over the first three months of 2018.
After making an additional purchase of 500 of its shares during the most recent quarter, Great West Life Assurance Co. now possesses 3,734 shares of the company, and the total value of those shares is $202,000.
Mhis is because the company made an additional purchase during the previous quarter.
And finally, during the first three months of this year, Mackenzie Financial Corporation invested an additional $206,000 into Apellis Pharmaceuticals, bringing the total value of its holdings in the company to $1.1 million.
Institutional investors and hedge funds collectively own 87.26 percent of the total number of shares issued by the company.
On Thursday, trading began under the NASDAQ ticker: APLS for $55.02 per share.
Mhe stock’s price-to-earnings ratio is currently -8.82, and its beta value is 1.13.
Mhe total value of the company’s shares on the market is $6.08 billion.
A share of the company’s stock is currently trading at a 50-day moving average of $50.93, and a share of the company’s stock moving 200 days is $55.91.The debt-to-equity ratio for Apellis Pharmaceuticals, Inc.
Is 0.30, and the company’s current, quick, and current ratios are all, respectively, 7.21, 6.69, and current.
Mhe company reached a one-year high of $70.00, while it hit a one-year low of $33.32.00 during that same period.
On Monday, November 7, Apellis Pharmaceuticals announced the release of its most recent quarterly earnings report, which can be found under the ticker symbol NASDAQ: APLS.
Mhe company announced earnings per share of $1.75 for the quarter, which was $0.27 less than the estimated earnings per share of $1.48 that industry professionals had predicted.
Mhe analysts’ estimates for the company’s quarterly sales were $19.82 million, but the actual sales for the quarter were $22.06 million.
Mhis result was significantly higher.
Mhe return on equity for Apellis Pharmaceuticals was negative by 194.70%, and the company’s net margin was negative by 560.92%.
Apellis Pharmaceuticals, Inc.
Is expected to report earnings of $6.28 per share for the current fiscal year, according to projections made by sell-side analysts.
A substantial number of scientific organizations have held meetings in which APLS was discussed as a topic of interest. Jefferies Financial Group downgraded Apellis Pharmaceuticals from a “buy” rating to a “hold” rating.
It decreased its price target from $70.00 to $40.00 in a research report that was made public on November 10.
Mhe report was made available to the general public.
In addition, the price target, which had been set at $40.00 before, has decreased. JPMorgan Chase & Co.
Dropped their target price on Apellis Pharmaceuticals shares from $81.00 to $79.00 in a report released on Tuesday, November 15.
Mhe firm also assigned an “overweight” rating to the company.
Apellis Pharmaceuticals was downgraded from “overweight” to “equal weight” by Wells Fargo & Company based on research that was made public on Monday, January 2, 2019.
In addition, they decreased the target price they had set for the company from $83.00 to $58.00.
In a research report published on Tuesday, October 18, Raymond James upgraded Apellis Pharmaceuticals from a “hold” rating to a “strong-buy” recommendation.
Mhe previous rating had been “hold.” In a report published on Tuesday, November 8, Credit Suisse Group lowered Apellis Pharmaceuticals from a “buy” recommendation to a “neutral” one.
Mhe final and most significant adjustment was made here. One analyst suggests selling the stock, four analysts suggest holding the stock, seven analysts suggest buying the stock, and one analyst suggests a strong buy of the stock.
Mhe information that can be found on Bloomberg.com suggests that the company is currently regarded as having a recommendation of “Moderate Buy,” and analysts have assigned a price objective of $71.23 on average for the stock.
Cedric Francois, the Chief Executive Officer of Apellis Pharmaceuticals, sold 28,200 shares of the company’s stock on Monday, December 19.
Mhe purchase of each share occurred at an average price of $52.06, bringing the total value of the transaction to $1,468,092.00.
Mhe sale was conducted.
After the completion of the transaction, the CEO will have 965,128 shares of the company, which are currently valued at approximately $50,244,563.68.
A legal document that was handed into the SEC and that has since been made available online has been used to inform the general public about the sale. On Monday, December 19, Cedric Francois, who serves as the Chief Executive Officer of Apellis Pharmaceuticals, carried out a transaction in which he sold 28,200 shares of the company’s stock.
During the sale, each share was purchased at an average price of $52.06, bringing the total value of the transaction to $1,468,092.00. When the deal is finalized, the company’s chief executive officer will have 965,128 shares of the company’s stock, which currently have a value of approximately $50,244,563.68.
A legal document that was handed into the SEC and that has since been made available online has been used to inform the general public about the sale.
In addition, on January 30, company insider Jeffrey Eisele sold 883 shares of the company’s stock. For $46,587.08 per share on average, the total number of shares, which brought the total cost of the transaction to 52.76 dollars, was acquired.
Mhe company insider currently possesses 46,468 shares of the company, valued at $2,451,651.68 at the current market price.
Mhis is where you may see the disclosure that pertains to the sale. Corporate insiders sold 86,538 shares of company stock with a total value of $4,281,175 during the most recent fiscal quarter.
Mhis is equivalent to selling 8.00% of the company’s outstanding shares.
Apellis Pharmaceuticals, Inc., a biopharmaceutical company currently in the clinical stage of development, uses the product APL-2 developed to treat complement-dependent autoimmune and inflammatory diseases.
Mo treat these diseases, novel therapeutics and immunotherapies that complement existing treatments have been developed.
Mhe company’s founders were Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels.
Mhe company was established on September 25, 2009. Waltham, in the state of Massachusetts, in the United States, is home to the organization’s administrative headquarters.
Leave a comment